NCT05022342 2026-02-23
SPEAR
Novartis
Completed
Clinical Trials
10 trialsNCT07096024 2025-08-28
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
Pfizer
Completed
NCT06525675 2024-12-13
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
MedSIR
Completed
NCT04916509 2023-06-06
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region
Pfizer
Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT05427617 2022-06-22
ACTDNAGLT
Hunan Cancer Hospital
Completed
NCT04524728 2020-08-24
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Istituti Clinici Scientifici Maugeri SpA
Completed
NCT04258163 2020-02-10
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
NCT01399086 2012-03-13
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
Hellenic Oncology Research Group
Completed
NCT00660803 2010-01-21
Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer
AstraZeneca
Completed